Nogapendekin alfa Inbakicept-pmln (Anktiva) with BCG: A Promising Arsenal in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Intervention.
作者信息
MohanaSundaram ArunSundar, Raja Velmurugan, Kamalakannan Yeshwanth, Islam Md Aminul
机构信息
School of Pharmacy, Sathyabama Institute of Science and Technology, Jeppiaar Nagar, Rajiv Gandhi Salai, Chennai 600119. Tamilnadu, India.
COVID-19 Diagnostic Lab, Department of Microbiology, Noakhali Science and Technology University, Noakhali-3814, Bangladesh.
出版信息
Adv Pharm Bull. 2025 Mar 29;15(1):4-6. doi: 10.34172/apb.43870. eCollection 2025 Apr.
Abstract
摘要
相似文献
1
Nogapendekin alfa Inbakicept-pmln (Anktiva) with BCG: A Promising Arsenal in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Intervention.诺加彭德金α英巴奇普-pmln（安克蒂瓦）联合卡介苗：卡介苗无反应性非肌肉浸润性膀胱癌干预的有前景的武器。
Adv Pharm Bull. 2025 Mar 29;15(1):4-6. doi: 10.34172/apb.43870. eCollection 2025 Apr.
2
Nogapendekin alfa Inbakicept: First Approval.尼戈宾卡丁-α（Inbakicept）：首个获批。
Drugs. 2024 Jul;84(7):867-874. doi: 10.1007/s40265-024-02060-1. Epub 2024 Jul 5.
3
Nogapendekin alfa inbakicept-PMLN: first approval milestone for BCG-unresponsive noninvasive bladder cancer: editorial.诺加彭德金α-免疫内肽酶-聚麦芽糖纳米粒：卡介苗无反应性非侵袭性膀胱癌的首个批准里程碑：社论
Ann Med Surg (Lond). 2024 Sep 20;86(11):6386-6388. doi: 10.1097/MS9.0000000000002591. eCollection 2024 Nov.
4
Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.卡介苗无反应性非肌层浸润性膀胱癌的保膀胱治疗：国际膀胱癌小组关于最佳治疗顺序和患者选择的建议
Eur Urol. 2024 Dec;86(6):516-527. doi: 10.1016/j.eururo.2024.08.001. Epub 2024 Aug 24.
5
Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer.高级别非肌层浸润性膀胱癌和局限性肌层浸润性膀胱癌的膀胱保留现状
Curr Oncol Rep. 2025 Apr 30. doi: 10.1007/s11912-025-01657-3.
6
In brief: Anktiva for bladder cancer.简而言之：用于膀胱癌的Anktiva。
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e105-e106. doi: 10.58347/tml.2024.1705e.
7
IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.白细胞介素-15 超级激动剂 NAI 在卡介苗无应答性非肌肉浸润性膀胱癌中的作用。
NEJM Evid. 2023 Jan;2(1):EVIDoa2200167. doi: 10.1056/EVIDoa2200167. Epub 2022 Nov 10.
8
Emerging bladder-sparing treatments for high risk non-muscle invasive bladder cancer.针对高危非肌层浸润性膀胱癌的新兴保膀胱治疗方法。
Bladder Cancer. 2025 Jun 26;11(2):23523735251348842. doi: 10.1177/23523735251348842. eCollection 2025 Apr-Jun.
9
Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group.卡介苗治疗失败的非肌层浸润性膀胱癌的未满足需求：国际膀胱癌小组的系统评价和成本效益分析
Eur Urol Oncol. 2025 Feb;8(1):216-229. doi: 10.1016/j.euo.2024.10.012. Epub 2024 Nov 15.
10
Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer.N-803 联合卡介苗治疗卡介苗无应答性非肌肉浸润性膀胱癌的 2/3 期试验中的生活质量。
Urol Pract. 2024 Mar;11(2):367-375. doi: 10.1097/UPJ.0000000000000517. Epub 2024 Jan 16.
本文引用的文献
1
Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group.卡介苗治疗失败的非肌层浸润性膀胱癌的未满足需求：国际膀胱癌小组的系统评价和成本效益分析
Eur Urol Oncol. 2025 Feb;8(1):216-229. doi: 10.1016/j.euo.2024.10.012. Epub 2024 Nov 15.
2
Comparison between N-803 and Erdafitinib in Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer.N-803与厄达替尼在卡介苗无反应性非肌肉浸润性膀胱癌中的比较
Cancers (Basel). 2024 Oct 11;16(20):3445. doi: 10.3390/cancers16203445.
3
Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC.BCG 无应答性非肌层浸润性膀胱癌不同治疗方式的成本效果分析。
BJU Int. 2024 Oct;134(4):582-588. doi: 10.1111/bju.16332. Epub 2024 Mar 16.
4
BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer.BCG 与非肌肉浸润性膀胱癌的 BCG 治疗替代疗法。
Curr Oncol. 2024 Feb 16;31(2):1063-1078. doi: 10.3390/curroncol31020079.
5
IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.白细胞介素-15 超级激动剂 NAI 在卡介苗无应答性非肌肉浸润性膀胱癌中的作用。
NEJM Evid. 2023 Jan;2(1):EVIDoa2200167. doi: 10.1056/EVIDoa2200167. Epub 2022 Nov 10.
6
Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.用于 BCG 无应答的高危非肌肉浸润性膀胱癌的新型免疫治疗选择。
Cancer Med. 2023 Dec;12(24):21944-21968. doi: 10.1002/cam4.6768. Epub 2023 Dec 1.
7
Re: IL-15 Superagonist NAI in BCG-Unresponsive Non-muscle-invasive Bladder Cancer.关于：卡介苗无反应性非肌层浸润性膀胱癌中的白细胞介素-15超激动剂NAI
Eur Urol. 2023 Jun;83(6):581. doi: 10.1016/j.eururo.2023.01.009. Epub 2023 Feb 1.
8
Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer.IL-15 类似物（N-803）联合卡介苗（BCG）治疗膀胱癌的安全性、耐受性和长期临床结局。
Oncoimmunology. 2021 May 3;10(1):1912885. doi: 10.1080/2162402X.2021.1912885.
9
Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.膀胱内注射ALT-803和卡介苗治疗可减轻致癌物诱导的膀胱癌大鼠模型中的肿瘤负担；细胞因子产生和自然杀伤细胞扩增的作用。
PLoS One. 2014 Jun 4;9(6):e96705. doi: 10.1371/journal.pone.0096705. eCollection 2014.
10
Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.膀胱原位癌且卡介苗治疗禁忌或失败的患者的膀胱内 VALrubicin。
Urol Oncol. 2013 Nov;31(8):1635-42. doi: 10.1016/j.urolonc.2012.04.010. Epub 2012 May 9.
Zotero 插件